Cargando…

Effect of Cilastatin on Cisplatin-Induced Nephrotoxicity in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy

Cisplatin is one of the most widely used chemotherapeutic agents in oncology, although its nephrotoxicity limits application and dosage. We present the results of a clinical study on prophylaxis of cisplatin-induced nephrotoxicity in patients with peritoneal carcinomatosis undergoing cytoreduction a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaballos, Matilde, Power, Mercedes, Canal-Alonso, María Iluminada, González-Nicolás, María Ángeles, Vasquez-Jimenez, Wenceslao, Lozano-Lominchar, Pablo, Cabrerizo-Torrente, Pilar, Palencia-García, Natividad, Gago-Quiroga, Susana, Ginel-Feito, María Dolores, Jiménez, Consuelo, Lázaro, Alberto, González-Bayón, Luis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7865672/ https://www.ncbi.nlm.nih.gov/pubmed/33513824 http://dx.doi.org/10.3390/ijms22031239

Ejemplares similares

Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity
por: Humanes, Blanca, et al.
Publicado: (2015)

FKBP51, AmotL2 and IQGAP1 Involvement in Cilastatin Prevention of Cisplatin-Induced Tubular Nephrotoxicity in Rats
por: González-Fernández, Rebeca, et al.
Publicado: (2022)

Cilastatin protects against tacrolimus-induced nephrotoxicity via anti-oxidative and anti-apoptotic properties
por: Luo, Kang, et al.
Publicado: (2019)

1951. Nephrotoxicity Associated With Imipenem/Cilastatin/Relebactam (IMI/REL) vs. Imipenem/Cilastatin Plus Colistin (IMI+CST) in Patients With Imipenem-Nonsusceptible (NS) Bacterial Infections
por: Brown, Michelle, et al.
Publicado: (2018)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
por: Huo, Xiaokui, et al.
Publicado: (2019)

Combination therapy of cisplatin with cilastatin enables an increased dose of cisplatin, enhancing its antitumor effect by suppression of nephrotoxicity
por: Arita, Masashi, et al.
Publicado: (2021)

Preoperative smoking cessation counseling activities of anesthesiologists: a cross-sectional study
por: Zaballos, Matilde, et al.
Publicado: (2015)

Imipenem-cilastatin-induced psychosis: a case report
por: Ninan, Jacob, et al.
Publicado: (2016)

Sodium thiosulfate for postoperative cisplatin induced nephrotoxicity following hyperthermic intraperitoneal chemotherapy: A case report
por: Patel, K., et al.
Publicado: (2021)

Hematological Alterations after Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
por: Pintado, Maria Consuelo, et al.
Publicado: (2023)

Appendiceal Mucinous Neoplasms: From Clinic to Pathology and Prognosis
por: González Bayón, Luis, et al.
Publicado: (2023)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin
por: Agudelo, Maria, et al.
Publicado: (2019)

Cilastatin: a potential treatment strategy against COVID-19 that may decrease viral replication and protect from the cytokine storm
por: González-Nicolás, María Ángeles, et al.
Publicado: (2020)

New evidence in severe pneumonia: imipenem/ cilastatin/relebactam
por: Girón, Rosa Mª, et al.
Publicado: (2022)

Anesthetic implications in hyperthermic intraperitoneal chemotherapy
por: Gupta, Nishkarsh, et al.
Publicado: (2019)

Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer
por: Riggs, McKayla J., et al.
Publicado: (2020)

Comparison of open and closed hyperthermic intraperitoneal chemotherapy: Results from the United States hyperthermic intraperitoneal chemotherapy collaborative
por: Leiting, Jennifer L, et al.
Publicado: (2020)

A Dose-Finding Trial for Hyperthermic Intraperitoneal Cisplatin in Gynecological Cancer Patients Receiving Hyperthermic Intraperitoneal Chemotherapy
por: Chan, Chui-ying, et al.
Publicado: (2021)

Nephroprotective Effect of Cilastatin against Gentamicin-Induced Renal Injury In Vitro and In Vivo without Altering Its Bactericidal Efficiency
por: Jado, Juan Carlos, et al.
Publicado: (2020)

Lipidomics Reveals Cisplatin-Induced Renal Lipid Alterations during Acute Kidney Injury and Their Attenuation by Cilastatin
por: Moreno-Gordaliza, Estefanía, et al.
Publicado: (2021)

Temperature management during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy
por: Ramirez, Maria F., et al.
Publicado: (2023)

Cytoreductive onco-surgery with combined hyperthermic intraperitoneal chemotherapy and hyperthermic intrathoracic chemotherapy: Perioperative challenges
por: Dattatri, Rohini, et al.
Publicado: (2019)

Comparison of Efficacy of Cefoperazone/Sulbactam and Imipenem/Cilastatin for Treatment of Acinetobacter Bacteremia
por: Choi, Jun Yong, et al.
Publicado: (2006)

Imipenem/Cilastatin/Relebactam: A Review in Gram-Negative Bacterial Infections
por: Heo, Young-A.
Publicado: (2021)

Cytoreduction with hyperthermic intraperitoneal chemotherapy: An anaesthetic challenge
por: Murughan, Kavita, et al.
Publicado: (2014)

Hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer
por: Wu, Tao, et al.
Publicado: (2018)

Single Center Experience With Hyperthermic Intraperitoneal Chemotherapy
por: Kim, Woo Ram, et al.
Publicado: (2017)

Hyperthermic Intraperitoneal Chemotherapy: A Critical Review
por: Ceelen, Wim, et al.
Publicado: (2021)

Oral Release Behavior of Wine Aroma Compounds by Using In-Mouth Headspace Sorptive Extraction (HSSE) Method
por: Pérez-Jiménez, María, et al.
Publicado: (2021)

Understanding human salivary esterase activity and its variation under wine consumption conditions
por: María, Pérez-Jiménez, et al.
Publicado: (2020)

Specificity of Saliva Esterases by Wine Carboxylic Esters and Inhibition by Wine Phenolic Compounds Under Simulated Oral Conditions
por: Pérez-Jiménez, María, et al.
Publicado: (2021)

Metabolic alkalosis: A less appreciated side effect of Imipenem-cilastatin use
por: Panda, Pragyan Swagatika, et al.
Publicado: (2013)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
por: Kabbara, Wissam K, et al.
Publicado: (2015)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
por: Shaaban, Mona I., et al.
Publicado: (2017)

Small bowel bleeding treated successfully with transcatheter arterial embolization with imipenem/cilastatin
por: Arima, Takahiro, et al.
Publicado: (2022)

Assessment of Hyperthermic Intraperitoneal Chemotherapy to Eradicate Intraperitoneal Free Cancer Cells()
por: Ji, Zhonghe, et al.
Publicado: (2016)

Hyperthermic intraperitoneal chemotherapy for ovarian cancer: is there a role?
por: Helm, C. William
Publicado: (2015)

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
por: Gamboa, Adriana C., et al.
Publicado: (2019)

Simulating drug penetration during hyperthermic intraperitoneal chemotherapy
por: Löke, Daan R., et al.
Publicado: (2021)

Hyperthermic intraperitoneal chemotherapy in ovarian cancer: Qui Bono?
por: Spiliotis, John
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_vpgava95u4vbalubv5m20qevqn